Equities

Truspine Technologies PLC

TSP:NXX

Truspine Technologies PLC

Actions
  • Price (GBX)2.00
  • Today's Change-0.06 / -2.91%
  • Shares traded168.18k
  • 1 Year change+66.67%
  • Beta--
Data delayed at least 15 minutes, as of May 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

TruSpine Technologies Plc is a United Kingdom-based medical device company focused on the spinal (vertebral) stabilization market. The Company's flagship spinal fixation devices include Cervi-LOK, GRASP Laminoplasty system and Faci-LOK. Cervi-LOK is a screw free spinal stabilization system, used in the cervical spine that minimizes risk of vertebral artery injury which can cause brainstem stroke or nerve root and spinal cord injury. GRASP Laminoplasty system is used in the treatment of decompression of the spinal cord. GRASP Laminoplasty system is both minimally invasive in application, and does not require the use of any screws, thereby avoiding damage to the bony anatomy with respect to its fixation and anchoring. Faci-LOK system takes advantage of anatomic features on the posterior aspect of the lumbar and lower thoracic vertebra that predispose themselves to the application of grasping anchors. Faci-LOK Anchor is formed by an upper (cranial) element and a lower (caudal) element.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-471.89k
  • Incorporated2014
  • Employees1.00
  • Location
    Truspine Technologies PLCSpectrum House, Gatwick AirportGATWICK RH6 0LGUnited KingdomGBR
  • Phone+44 207 118 0852
  • Websitehttp://truspine.org/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Deltex Medical Group plc1.78m-1.28m2.18m37.00--0.6457--1.23-0.0012-0.00120.00150.00180.29740.84715.6148,000.00-21.47-14.66-29.13-21.8163.3471.84-72.18-32.931.13-2.980.3793---28.44-18.55-11.97--9.78--
Image Scan Holdings Plc2.56m-11.06k2.39m14.00--1.7225.980.9337-0.00008-0.000080.01870.01021.072.385.38183,209.30-0.4626-1.15-0.7257-1.7750.5751.36-0.4312-1.011.69--0.00--47.98-3.08145.65--40.19--
Truspine Technologies PLC0.00-471.89k3.14m1.00--1.10-----0.004-0.0040.000.02050.00----0.00-13.14-21.97-16.58-26.49-----------32.310.0984------23.29--21.72--
Surgical Innovations Group Plc12.01m-509.00k4.66m90.00--0.444918.810.3882-0.0005-0.00050.01290.01120.80322.855.89---3.40-8.19-4.18-9.9428.7032.51-4.24-13.311.23-4.450.1368--5.941.84-292.80--7.20--
Myhealthchecked PLC14.95m189.00k5.85m15.0030.320.684317.680.39150.00370.00370.28850.16441.265.817.95996,400.001.59-20.092.21-28.2327.7922.621.26-13.423.53--0.0047--36.26190.36-24.30---12.80--
Rua Life Sciences PLC1.87m-1.87m7.91m40.00--0.7575--4.23-0.0843-0.08430.08430.16830.32933.264.8046,725.00-32.95-25.97-36.33-28.2681.97---100.05-110.532.40-61.710.1065--34.0940.083.10--94.82--
Inspiration Healthcare Group PLC41.08m-550.00k11.16m210.00--0.31676.630.2716-0.0081-0.00810.6030.51630.78792.324.76195,619.00-1.056.14-1.257.6045.5947.42-1.346.001.50-0.12890.2317--0.445821.62-93.58-25.9752.54--
Data as of May 22 2024. Currency figures normalised to Truspine Technologies PLC's reporting currency: UK Pound GBX
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.